IRD vs UNH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. Most alarming is the negative gross margin of -117.05%, meaning the company loses money on every unit of revenue generated before operating expenses. Despite a speculative 654.9% price surge over the last year and a 'strong_buy' analyst consensus, the underlying data shows declining revenue (-10.20%) and extreme valuation multiples (P/B of 24.36). The stock appears to be trading on momentum or speculative expectations rather than any tangible financial health.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.